- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
|Catalog||Size (Price)||Quantity||In Stock||Operation|
IGFBP7 Antibody Datasheet
|Order or Inquire for IGFBP7 Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.15625 ng/well in ELISA|
IGFBP7 Antibody Product Information
Recombinant Human IGFBP7 protein (Catalog#13100-H08H)
|Antibody Type :||Mouse Monoclonal Antibody ( Mouse mAb Service Platform )|
Clone ID :
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.|
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IGFBP7 (rh IGFBP7; Catalog#13100-H08H; Q16270; Met 1-Leu 282). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
IGFBP7 Antibody Usage Guide
No cross-reactivity in ELISA with
Human IGFBP6Human cell lysate (293 cell line)
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human IGFBP7. The detection limit for Human IGFBP7 is approximately 0.15625 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
IGFBP7 Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|IGFBP7||Human||IGFBP7 Protein, Recombinant||13100-H02H|
|IGFBP7||Human||IGFBP7 Protein, Recombinant||13100-H08H|
|IGFBP7||Human||IGFBP7 / IBP-7 Protein, Recombinant||13100-H07H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human IGFBP7||ELISA, IHC-P||IGFBP7 Antibody (Antigen Affinity Purified)||13100-RP02|
|Human IGFBP7||ELISA||IGFBP7 Antibody||13100-MM01|
IGFBP7 Antibody Background
Insulin-like growth factor-binding protein 7, also known as IGF-binding protein 7, IBP-7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor TAF and IGFBP7, is a secreted protein involved in several cellular processes, including proliferation, senescence and apoptosis. Loss of IGFBP7 expression is a critical step in the development of human tumors, including melanoma and colon cancer. IGFBP7 contains oneIg-like C2-type (immunoglobulin-like) domain, oneIGFBP N-terminal domain and one Kazal-like domain. IGFBP7 binds IGF-I and IGF-II with a relatively low affinity. IGFBP7 stimulates prostacyclin (PGI2) production. It also stimulates cell adhesion. The major function of the IGFBP7 protein is in the regulation of availability ofInsulin like growth factors (IGFs) in tissue as well as in modulating IGF binding to its receptors. IGFBP7 binds to IGF with high affinity. It also stimulates cell adhesion. IGFBP7 protein is implicated in some cancers.
- Akaogi K. et al.,1994, Biochem Biophys Res Commun. 198: 1046-53.
- Oh Y. et al., 1996, J Biol Chem. 271: 30322-30325.
- Wilson EM. et al., 2001, J Clin Endocrinol Metab. 86: 4504-4511.
- Sanjida Ahmed., et al., 2006, FEBS Journal.273 (3): 615-27.
- Gommans WM., et al., 2008, RNA. 14: 2074-2085.
- Vizioli MG. et al., 2010, Oncogene. 29 (26): 3835-44.